Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Summary

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

Timeline

Start

2019-08-09

Primary completion

2022-09-20

Completion

2022-12-23

Drugs

Indications